Moreover, the association of low TFRC expression in tumour specimens with enhanced responsiveness to anti‐PD‐1‐based immunotherapy suggests that TFRC levels could serve as a biomarker for predicting the treatment efficacy of anti‐PD‐1‐based approaches in HCC patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.